Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.
Setmelanotide is associated with high rates of injection-site reactions and skin hyperpigmentation, necessitating careful patient monitoring.
Where it sits
this study against the rest of the setmelanotide corpusSummary and findings
This study assessed the adverse event profile of setmelanotide in individuals with genetically determined obesity. The analysis included data from the USFDA Adverse Event Reporting System, case reports, and clinical trials. Key findings included high rates of specific adverse events such as injection-site reactions and skin hyperpigmentation.
Abstract
<h4>Background</h4>Setmelanotide is approved for genetically determined obesity. While clinical trials and clinical evidence and practice provide some insights, a comprehensive assessment of its adverse event profile is needed that led to carrying out an assessment of reported adverse events in the USFDA Adverse Event Reporting System database, case reports and clinical trials.<h4>Research design and methods</h4>Multi-faceted analyses were carried out as follows: disproportionality measures employing frequentist and Bayesian methods; systematic review and meta-analysis (Medline, Cochrane CENTRAL and Google Scholar) generated-pooled estimates [proportion with 95% confidence intervals (CI)]; and published reports with adverse events to setmelanotide.<h4>Results</h4>The disproportionality analysis (<i>n</i> = 228) identified skin hyperpigmentation, injection-site reactions, nausea, melanocytic nevus and ephelides as key safety signals. Meta-analysis (seven trials; <i>n</i> = 185) confirmed high rates of injection-site reactions (96%; 95% CI: 89, 100), skin hyperpigmentation (62%; 95% CI: 43, 78), nausea (36%; 95% CI: 24, 49), vomiting (26%; 95% CI: 18, 34), and diarrhea (21%; 95% CI: 14, 29). Individual case reports corroborated these findings.<h4>Conclusion</h4>This study provides a detailed overview of setmelanotide's adverse event profile, highlighting the need for careful patient monitoring, emphasizing the importance of ongoing safety surveillance for at least 1.5 years, and further research to refine patient management strategies.
Background
This paper addresses the need for a comprehensive assessment of the adverse event profile of setmelanotide, which is approved for genetically determined obesity. Previous studies have provided some insights into its safety, but a systematic review and integrated assessment were necessary to consolidate this information. Understanding the adverse events associated with setmelanotide is crucial for patient management and safety monitoring.
Methods
The study employed multi-faceted analyses, including disproportionality measures using frequentist and Bayesian methods. A systematic review and meta-analysis were conducted using data from Medline, Cochrane CENTRAL, and Google Scholar. The primary outcome measures focused on the proportion of reported adverse events.
Results
The disproportionality analysis identified key safety signals, including skin hyperpigmentation and injection-site reactions, from a total of 228 reports. The meta-analysis confirmed high rates of adverse events: 96% for injection-site reactions, 62% for skin hyperpigmentation, 36% for nausea, 26% for vomiting, and 21% for diarrhea, with respective 95% confidence intervals provided.
Interpretation
The findings indicate a significant prevalence of certain adverse events associated with setmelanotide, particularly injection-site reactions and skin hyperpigmentation. While the statistical significance of these findings is clear, the clinical significance may vary among patients. Limitations include reliance on reported data, which may not fully represent the adverse event landscape, and potential biases in reporting.
Key findings
- 96% injection-site reactions, 95% CI: 89, 100, n=185.
- 62% skin hyperpigmentation, 95% CI: 43, 78, n=185.
- 36% nausea, 95% CI: 24, 49, n=185.
- 26% vomiting, 95% CI: 18, 34, n=185.
- 21% diarrhea, 95% CI: 14, 29, n=185.
Limitations
- data from USFDA Adverse Event Reporting System may not capture all adverse events
- potential reporting biases in case reports
- meta-analysis limited to seven trials, n=185